BioXpress Therapeutics

BioXpress Therapeutics is a Swiss biotechnology company specializing in the development of high-quality biosimilar monoclonal antibodies (mAbs). The company focuses on creating more affordable versions of blockbuster biologics used in oncology and inflammatory diseases. Their pipeline includes biosimilar candidates for widely used therapies such as adalimumab, trastuzumab, and infliximab. BioXpress utilizes a lean, virtual business model to advance its programs through clinical development by leveraging a network of expert partners. The company aims to improve global patient access to essential biologic treatments through strategic collaborations.